A Dose-escalation Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of Single Dose of EDP167 Injection in Healthy Volunteers and Subjects With Mild Dyslipidemia
Latest Information Update: 24 Feb 2026
At a glance
- Drugs EDP 167 (Primary)
- Indications Dyslipidaemias
- Focus Adverse reactions
- Sponsors Eddingpharm
Most Recent Events
- 24 Feb 2026 New trial record